Stocks / Healthcare

OUTLOOK THERAPEUTICS INC

OTLK Stock Report
Current Price
XXXX
Analyst Target Price
$8.25
Market Cap
XXXX
Updated
September 9, 2025
Analysts
6

OUTLOOK THERAPEUTICS INC Stock Overview

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product… More details ➜
1 Year Price Range
Low $0.79 Current High $7.26
PinkLion Scores

Fundamentals Summary

P/E Ratio
-
P/S Ratio
27.34x
Net Income
Revenue
Market Cap

Net Income & Revenue

Last Reported Earnings
June 30, 2025
Earnings per share (EPS) $-0.84
Gross Margin -2,681.93%
Net Profit Margin -
Debt/Equity Ratio -47.51%

Dividends

Current Dividend Yield
-
Payout Ratio
-
Forward Dividend Yield
-

Price History

Track historical stock performance, price trends, and volatility for OTLK to see how the stock has performed over time.
YTD
1 Year
5 Years
All

Valuation Summary

We estimate a fair price for OTLK by projecting its future cash flows and discounting them back to today with a XXXXX model.

About the Company

IPO Date
May 13, 2016
Employees
23
Sector
Healthcare
Industry
Biotechnology
Country
USA
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.